Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Type 2 diabetes
Biotech
Alnylam abandons clinical-stage Type 2 diabetes asset
Alnylam is suspending further development of a clinical-stage RNAi therapeutic designed to treat Type 2 diabetes among participants with obesity.
Gabrielle Masson
Oct 31, 2024 10:27am
Chinese insulin maker’s GLP-1 bests Ozempic in ph. 2, company says
Oct 15, 2024 11:12am
Lilly posts more positive data on once-weekly insulin prospect
Sep 11, 2024 2:05pm
Lilly posts more positive data on its weekly insulin prospect
Sep 5, 2024 6:45am
Embecta's insulin patch pump secures FDA nod in Type 2 diabetes
Sep 3, 2024 2:29pm
ProKidney halts ph. 3 trial not needed for cell therapy approval
Sep 3, 2024 8:55am
